Back to discover
Drug

Figitumumab

Early clinical development
ClassInsulin-like growth factor I receptor antagonist
RxNorm1392801ChEMBLCHEMBL1743019UNIIVE267FC2UB
IGF1R
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Figitumumab
RxNorm CUI
1392801
ChEMBL ID
CHEMBL1743019
UNII
VE267FC2UB
Primary mechanism
Insulin-like growth factor I receptor antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Insulin-like growth factor 1 receptor
IGF1R · P08069
ANTAGONISTInsulin-like growth factor I receptor antagonist

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
3
Discontinued
PHASE DISTRIBUTIONn = 3
Phase 12Phase 21
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials